Connection

Campbell McInnes to Protein Binding

This is a "connection" page, showing publications Campbell McInnes has written about Protein Binding.
Connection Strength

1.013
  1. Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor. ChemMedChem. 2020 06 17; 15(12):1058-1066.
    View in: PubMed
    Score: 0.143
  2. Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation. J Med Chem. 2019 04 25; 62(8):3886-3897.
    View in: PubMed
    Score: 0.133
  3. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors. J Vis Exp. 2015 Oct 26; (105):e52441.
    View in: PubMed
    Score: 0.104
  4. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity. J Med Chem. 2015 Jan 08; 58(1):433-42.
    View in: PubMed
    Score: 0.098
  5. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype. Mol Cancer Ther. 2012 Aug; 11(8):1683-92.
    View in: PubMed
    Score: 0.083
  6. Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements. ACS Chem Biol. 2010 Dec 17; 5(12):1169-82.
    View in: PubMed
    Score: 0.074
  7. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. Biochem Pharmacol. 2009 May 15; 77(10):1561-71.
    View in: PubMed
    Score: 0.065
  8. Virtual screening strategies in drug discovery. Curr Opin Chem Biol. 2007 Oct; 11(5):494-502.
    View in: PubMed
    Score: 0.060
  9. Improved lead-finding for kinase targets using high-throughput docking. Curr Opin Drug Discov Devel. 2006 May; 9(3):339-47.
    View in: PubMed
    Score: 0.054
  10. Strategies for the design of potent and selective kinase inhibitors. Curr Pharm Des. 2005; 11(14):1845-63.
    View in: PubMed
    Score: 0.049
  11. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol. 2004 Apr; 11(4):525-34.
    View in: PubMed
    Score: 0.047
  12. Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones. Protein Expr Purif. 2015 Sep; 113:8-16.
    View in: PubMed
    Score: 0.025
  13. Structural characterization of the binding interactions of various endogenous estrogen metabolites with human estrogen receptor a and ? subtypes: a molecular modeling study. PLoS One. 2013; 8(9):e74615.
    View in: PubMed
    Score: 0.023
  14. Calpain 10 homology modeling with CYGAK and increased lipophilicity leads to greater potency and efficacy in cells. ACS Chem Biol. 2012 Aug 17; 7(8):1410-9.
    View in: PubMed
    Score: 0.021
  15. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol. 2005 Jul 15; 350(3):587-98.
    View in: PubMed
    Score: 0.013
  16. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure. 2003 Dec; 11(12):1537-46.
    View in: PubMed
    Score: 0.011
  17. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure. 2003 Apr; 11(4):399-410.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.